Coming soon · Book Profile
The Antidote Inside the World of New Pharma
The book follows the biotech firm Vertex Pharmaceuticals over two decades as it battles scientific challenges, fierce competition, and financial uncertainty to develop breakthrough drugs for serious diseases like Hepatitis C and Cystic Fibrosis.
A profile of this book is on the way.
What it’s about
Twenty years after chronicling its audacious beginnings in "The Billion-Dollar Molecule," author Barry Werth returns inside Vertex Pharmaceuticals to tell the full story of its grueling quest to transform modern medicine. This book is an intimate, high-stakes narrative of scientific discovery and corporate survival, detailing Vertex's journey from a cash-starved startup to a biopharmaceutical powerhouse. It reveals the staggering scientific, financial, and human challenges of creating life-saving drugs atom-by-atom for diseases like AIDS, Hepatitis C, and Cystic Fibrosis. Against the backdrop of a broken and risk-averse pharmaceutical industry, Vertex’s story is an inspiring testament to the power of a fearless, innovation-driven culture and a relentless focus on patients, offering a glimpse into the future of medicine and the immense effort it takes to bring a "game-changing" product from the lab to the people who need it most.
The through-line
- Who it’s for
- The reader is an innovator, entrepreneur, scientist, or business leader who is frustrated with bureaucratic, risk-averse environments and the slow pace of meaningful progress. They want to understand how to build an organization that can tackle monumental challenges and create truly transformative products that change the world.
- The problem
- The existing models for innovation, particularly in industries like pharmaceuticals, are broken, slow, and often prioritize incremental gains and marketing over genuine breakthroughs. It's incredibly difficult to build a sustainable organization focused on high-risk, high-reward projects. The reader feels constrained, impatient, and perhaps cynical about the possibility of creating lasting impact within large, established systems. They question whether a mission-driven, science-first approach can truly succeed against profit-obsessed behemoths.
- The plan
- Embrace a Bold Vision: Learn how Vertex's founder, Joshua Boger, articulated a clear, audacious goal to design drugs atom-by-atom for the world's hardest diseases.
- Cultivate a Resilient Culture: Discover the core values ('Fearless pursuit of excellence', 'Innovation is our lifeblood', '"We" wins') that enabled Vertex to endure billions in losses and decades of setbacks.
- Navigate the Business Realities: Follow the strategic deal-making, partnerships, and financial maneuvering required to fund long-term R&D in a world driven by quarterly results.
- Execute Relentlessly: Witness the operational buildout—from R&D to manufacturing to commercial sales—required to bring a drug from a lab concept to a global product.
- The payoff
- The reader will be equipped with a real-world model for leadership and innovation, capable of building a resilient, mission-driven organization that can tackle audacious goals and achieve breakthrough success. · They will feel inspired and armed with the strategic knowledge to challenge industry norms and persevere through failure.
See our guide
Related profiles we’ve built
- Time Series Forecasting Using Foundation Models →
- Understanding Deep Learning →
- The AI Marketing Canvas: A Five-Step AI Plan for Marketers →
- Artificial Intelligence →
- Artificial Intelligence - A Very Short Introduction →
- Effective Data Science Infrastructure →
- Human + Machine →
- Big Data_ A Very Short Introduction (Very Short Introductions) →
Additional reading
- Dianetics: The Modern Science of Mental Health · L. Ron Hubbard
This foundational text of Scientology deeply influenced Bob Duggan's worldview and management style, which he credited for his business success at Pharmacyclics.
- Article on 24 characteristics of geniuses · Alfred Barrios
Originally published in the National Enquirer, this article formed the basis of Bob Duggan's 'Genius' corporate training program at Pharmacyclics, a core part of his unconventional leadership.
- The Billion-Dollar Molecule · Barry Werth
The author's first book on Vertex, providing the detailed backstory of the company's founding, its initial scientific mission, and the people who established its culture.
- Built to Last: Successful Habits of Visionary Companies · Jim Collins and Jerry Porras
This book's concepts, particularly the 'Big Hairy Audacious Goal' (BHAG), were explicitly used by Vertex leadership to frame and execute its long-term strategic and cultural development process.
- Zenobia: The Curious Book of Business · Matthew Emmens and Beth Kephart
Written by Joshua Boger's successor as CEO, this book outlines the management philosophy Emmens brought to Vertex as he guided its transition into a commercial organization.
- Pharmaplasia · Michael Wokasch
Mentioned in the afterword, this book provides a critical diagnosis of the ills of 'Big Pharma'—'rapid uncontrolled growth'—which Vertex was founded to be an 'antidote' to.
- The Eighth Day of Creation · Horace Freeland Judson
The book cites this as a key source for understanding the revolution in molecular biology, providing the broad scientific context in which Vertex was founded.
- The Puzzle People · Thomas E. Starzl
This autobiography is cited as an invaluable source for understanding Dr. Starzl's work, which is central to the story of FK-506 and the clinical landscape Vertex sought to enter.
- Gene Dreams · Robert Teitleman
The book refers to this as the 'best primer' on the biotech industry, offering essential background on the business environment, financial challenges, and competitive pressures facing startups like Vertex.
- Illness as Metaphor · Susan Sontag
The book frequently references Sontag's work to discuss how society uses punitive and mystifying metaphors for diseases like cancer and tuberculosis, and how these metaphors shape the patient's experience.